MedTrace Logo

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

NCT01314911 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 716

Last updated 2019-02-05

Study results available
· View outcomes & findings →

Summary

People who are infected with the influenza virus may develop respiratory illnesses, such as pneumonia, or other life-threatening complications. Currently, there are four antiviral medications that are used to treat influenza. This study will examine one of these medications, oseltamivir, to examine how it affects the shedding of influenza virus in infected people.

Conditions

  • Influenza, Human

Interventions

DRUG

Oseltamivir

Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.

DRUG

Placebo

Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • John Beigel, MD · Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, National Institutes of Health

  • Michael Ison, MD, MS · Division of Infectious Disease, Feinberg School of Medicine, Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2017-11-18
Completion
2017-11-18

Countries

  • United States
  • Argentina
  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01314911 on ClinicalTrials.gov